Skip to main content
. Author manuscript; available in PMC: 2017 Aug 30.
Published in final edited form as: JAMA Neurol. 2016 Mar;73(3):308–315. doi: 10.1001/jamaneurol.2015.4315

Table 3.

Baseline Factors Related to the Primary End Point in the SAMMPRIS Trial Medical Group in Multivariable Analysis

Factor Hazard Ratio (95% CI) P Value
Old infarct in the territory, yes vs no 2.6 (1.3-5.3) .006
Absence of statin use at enrollment, yes vs no 2.4 (1.1-5.2) .03
Qualifying event, stroke vs transient ischemic attack 3.0 (1.1-7.7) .03